Biological: oral polio vaccine — Competitive Intelligence Brief

Biological: oral polio vaccine (Biological: oral polio vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated viral vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated viral vaccine Poliovirus types 1, 2, and 3 Immunology / Infectious Disease Biologic

Target snapshot

Biological: oral polio vaccine (Biological: oral polio vaccine) — Biomed Industries, Inc.. Oral polio vaccine stimulates the immune system to produce antibodies against poliovirus types 1, 2, and 3 by delivering live attenuated (weakened) virus that replicates in the gastrointestinal tract.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Biological: oral polio vaccine TARGET	Biological: oral polio vaccine	Biomed Industries, Inc.	phase 3	Live attenuated viral vaccine	Poliovirus types 1, 2, and 3
sIPV batch 3	sIPV batch 3	Institute of Medical Biology, Chinese Academy of Medical Sciences	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
oral polio vaccine + information	oral polio vaccine + information	Bandim Health Project	marketed	Live attenuated vaccine	Poliovirus types 1, 2, and 3
sIPV batch 1	sIPV batch 1	Institute of Medical Biology, Chinese Academy of Medical Sciences	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
fIPV (0.1 mL) ID	fIPV (0.1 mL) ID	Centers for Disease Control and Prevention	marketed	vaccine	poliovirus types 1, 2, and 3 antigens
IPV at 6 weeks of age	IPV at 6 weeks of age	Centers for Disease Control and Prevention	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
DTacP-IPV combined vaccine (TETRAXIM™)	DTacP-IPV combined vaccine (TETRAXIM™)	Sanofi	marketed	Combination inactivated vaccine	Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated viral vaccine class)

1. Jean-Pierre Van geertruyden · 2 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Centers for Disease Control and Prevention · 1 drug in this class
4. GlaxoSmithKline · 1 drug in this class
5. Hospital Clinic of Barcelona · 1 drug in this class
6. Institute of Medical Biology, Chinese Academy of Medical Sciences · 1 drug in this class
7. Institute of Tropical Medicine, Belgium · 1 drug in this class
8. International Vaccine Institute · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class
10. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class